-
Eliana Cabrera,
Mariana González Murguiondo,
Marelina González Arias,
Carolina Arredondo,
Cristina Pintos, Gabriela Aguirre,
Marcelo Fernández,
Yester Basmadjián,
Raquel Rosa,
José Pedro Pacheco,
Stella Raymondo,
Rossanna Di Maio,
Mercedes González,
Hugo Cerecetto
[show abstract]
[hide abstract]
ABSTRACT: Ten 5-nitro-2-furyl derivatives, with good to excellent in vitro anti-Trypanosoma cruzi activity, and nifurtimox were tested oral and intraperitoneally on healthy animals for its acute toxicity on murine models. According to animals' survival percentage, organ histological results, biochemical and haematological findings, three new derivatives, with toxicity like nifurtimox, were selected to test in vivo as antichagasic agents. Clearly, dependences between chemical structure and both acute toxicity and in vivo anti-T. cruzi activity were observed. 4-Hexyl-1-[3-(5-nitro-2-furyl)-2-propenylidene]semicarbazide displayed good profile as anti-T. cruzi agent and better acute toxicity profile than nifurtimox.
European journal of medicinal chemistry 05/2009; 44(10):3909-14. · 3.27 Impact Factor
-
Marisol Vieites,
Lucía Otero,
Diego Santos,
Claudio Olea-Azar,
Ester Norambuena, Gabriela Aguirre,
Hugo Cerecetto,
Mercedes González,
Ulrike Kemmerling,
Antonio Morello,
Juan Diego Maya,
Dinorah Gambino
[show abstract]
[hide abstract]
ABSTRACT: Eight new platinum(II) complexes with 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-trypanosomal activity were synthesized, characterized and in vitro evaluated. Most of the complexes showed IC(50) values in the micromolar range against two different strains of Trypanosoma cruzi, causative agent of Chagas disease (American Trypanosomiasis). In addition, most of the newly developed complexes, together with the analogous platinum 5-nitrofuraldehyde containing thiosemicarbazones previously reported, resulted more active than the reference trypanocidal drug nifurtimox on the infective trypomastigote form of the parasite. Their capacity to produce free radicals that could lead to parasite death was evaluated by ESR experiments in the parasite and by respiration measurements. Compounds were tested for their DNA interaction ability. Results showed that some of the compounds could act as dual inhibitors in the parasite, through production of toxic free radicals and interaction with DNA. All the results were compared with those previously reported for the free ligands, the analogous palladium(II) compounds and the previously reported series of platinum(II) compounds.
Journal of inorganic biochemistry 01/2009; 103(3):411-8. · 3.25 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: In this paper, we report the structural design, synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazone (NAH) derivatives, planned as cruzain inhibitors candidates, a cysteine protease essential for the survival of Trypanosoma cruzi within the host cell. The salicylaldehyde N-acylhydrazones 7a and 8a presented IC(50) values of the same magnitude order than the standard drug nifurtimox (Nfx), when tested in vitro against epimastigote forms of Trypanosoma cruzi (Tulahuen 2 strain) and were non-toxic at the highest assayed doses rendering selectivity indexes (IC(50) (macrophages)/IC(50) (Trypanosoma cruzi)) of >25 for 7a and >20 for 8a, with IC(50) values in macrophages >400 microM.
Bioorganic & medicinal chemistry 12/2008; 17(2):641-52. · 2.82 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A series of over a hundred furoxans, alkylnitrates and related compounds were studied as growth inhibitors of the two major kinetoplastids of Latin America, Trypanosoma cruziand Leishmania spp., in in vitro assays. The most active compounds showed 50% inhibitory doses of the same order of that of Nifurtimox and Miltefosine, reference drugs used to treat Chagas Disease and Leishmaniasis respectively. Among the studied compounds derivative 4, presenting excellent inhibitory activity against the tryposmastigote and amastigote forms of T. cruzi, has emerged as a lead compound. Mechanism of action seems to involve mitochondrial dehydrogenases as a distinct effect with respect to Nifurtimox. Excreted metabolites, studied by NMR, showed a significant decrease in succinate, confirming the observed effect on the mitochrondrial dehydrogenases.
Bioorganic & medicinal chemistry 10/2008; 16(17):7900-7. · 2.82 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: New indazole derivatives have been developed to know about structural requirements for adequate anti-Trypanosoma cruzi activity. In relation to position 1 of indazole ring, we have observed that a butylaminopentyl substituent (14) affords good activity, but N-oxidation of omega-tertiary amino moiety yields completely inactive compounds (17, 18); the substituent at position 3 of indazole ring affects drastically the in vitro activity, 3-OH derivative 13 being completely inactive. On the other hand, since compound 22, denitro-analogue of active compound 4, does not show activity, the 5-nitro substituent of indazole ring seems to be essential. Intramolecular cyclization of side chain at position 1 also affords inactive compounds (19, 20). The electrochemical studies showed that the trypanocidal 5-nitroindazole derivatives yielded nitro-anion radical via one-electron process at physiological pH. This electrochemical behaviour occurs in the parasite according to ESR experiment with the T. cruzi microsomal fraction showing that 5-nitroindazole derivatives suffer bio-reduction without reactive oxygen species generation.
European journal of medicinal chemistry 08/2008; 44(4):1545-53. · 3.27 Impact Factor
-
Marisol Vieites,
Pablo Smircich,
Beatriz Parajón-Costa,
Jorge Rodríguez,
Verónica Galaz,
Claudio Olea-Azar,
Lucía Otero, Gabriela Aguirre,
Hugo Cerecetto,
Mercedes González,
Alicia Gómez-Barrio,
Beatriz Garat,
Dinorah Gambino
[show abstract]
[hide abstract]
ABSTRACT: In the search for new therapeutic tools against Chagas disease (American trypanosomiasis) palladium and platinum complexes of the bioactive ligand pyridine-2-thiol N-oxide were exhaustively characterized and evaluated in vitro. Both complexes showed high in vitro growth inhibition activity (IC(50) values in the nanomolar range) against Trypanosoma cruzi, the causative agent of the disease. They were 39-115 times more active than the antitrypanosomal drug Nifurtimox. The palladium complex showed an approximately threefold enhancement of the activity compared with the parent compound. In addition, owing to their low unspecific cytotoxicity on mammalian cells, the complexes showed a highly selective antiparasite activity. To get an insight into the mechanism of action of these compounds, DNA, redox metabolism (intraparasite free-radical production) and two parasite-specific enzymes absent in the host, namely, trypanothione reductase and NADH-fumarate reductase, were evaluated as potential parasite targets. Additionally, the effect of metal coordination on the free radical scavenger capacity previously reported for the free ligand was studied. All the data strongly suggest that trypanocidal action of the complexes could mainly rely on the inhibition of the parasite-specific enzyme NADH-fumarate reductase.
JBIC Journal of Biological Inorganic Chemistry 07/2008; 13(5):723-35. · 3.29 Impact Factor
-
Anayive Pérez-Rebolledo,
Letícia R Teixeira,
Alzir A Batista,
Antonio S Mangrich, Gabriela Aguirre,
Hugo Cerecetto,
Mercedes González,
Paola Hernández,
Ana M Ferreira,
Nivaldo L Speziali,
Heloisa Beraldo
[show abstract]
[hide abstract]
ABSTRACT: N(4)-methyl-4-nitroacetophenone thiosemicarbazone (H4NO(2)Ac4M, 1), N(4),N(4)-dimethyl-4-nitroacetophenone thiosemicarbazone (H4NO(2)Ac4DM, 2) and N(4)-piperidyl-4-nitroacetophenone thiosemicarbazone (H4NO(2)Ac4Pip, 3) and their copper(II) complexes [Cu(4NO(2)Ac4M)(2)] (4), [Cu(4NO(2)Ac4DM)(2)] (5) and [Cu(4NO(2)Ac4Pip)(2)] (6) were tested for their in vitro ability to inhibit the growth of Trypanosoma cruzi epimastigote forms. H4NO(2)Ac4DM (2), [Cu(4NO(2)Ac4M)(2)] (4) and [Cu(4NO(2)Ac4DM)(2)] (5) proved to be as active as the clinical reference drugs nifurtimox and benznidazol. Taking into consideration the serious side effects and the poor efficacy of the reference drugs, as well as the appearance of resistance during treatment, the studied compounds could constitute a new class of anti-trypanosomal drug candidates.
European Journal of Medicinal Chemistry 06/2008; 43(5):939-48. · 3.35 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Two different families of N-oxide containing heterocycles were evaluated as in vitro growth inhibitors of T. cruzi. Both families of heterocycles were selected from our in-house library of compounds as analogues of active anti-T. cruzi N-oxide containing heterocycles. Derivatives from pyrimido[1,2-a]quinoxaline 6-oxide family were poorly active at the assayed doses. However, phenazine 5,10-dioxide derivatives displayed good to excellent anti-T. cruzi activities. The anti-T. cruzi activity of phenazine derivatives was related to substituent' electronic descriptors, sigma(p)(-). Derivatives 19, 20 and 23 were the most cytotoxic compounds against the protozoan and became excellent hit for further structural modifications.
European Journal of Medicinal Chemistry 12/2007; 43(8):1737-41. · 3.35 Impact Factor
-
Williams Porcal,
Paola Hernández,
Mariana Boiani, Gabriela Aguirre,
Lucía Boiani,
Agustina Chidichimo,
Juan J Cazzulo,
Nuria E Campillo,
Juan A Paez,
Ana Castro,
R Luise Krauth-Siegel,
Carolina Davies,
Miguel Angel Basombrío,
Mercedes González,
Hugo Cerecetto
[show abstract]
[hide abstract]
ABSTRACT: New benzofuroxans were developed and studied as antiproliferative Trypanosoma cruzi agents. Compounds displayed remarkable in vitro activities against different strains, Tulahuen 2, CL Brener and Y. Its unspecific cytotoxicity was evaluated using human macrophages being not toxic at a concentration at least 8 times, and until 250 times, that of its T. cruzi IC50. Some biochemical pathways were studied, namely parasite respiration, cysteinyl active site enzymes and reaction with glutathione, as target for the mechanism of action. Not only T. cruzi respiration but also Cruzipain or trypanothione reductase were not affected, however the most active derivatives, the vinylsulfinyl- and vinylsulfonyl-containing benzofuroxans, react with glutathione in a redox pathway. Furthermore, the compounds showed good in vivo activities when they were studied in an acute murine model of Chagas' disease. The compounds were able to reduce the parasite loads of animals with fully established T. cruzi infections.
Journal of Medicinal Chemistry 12/2007; 50(24):6004-15. · 5.25 Impact Factor
-
Williams Porcal,
Paola Hernández, Gabriela Aguirre,
Lucía Boiani,
Mariana Boiani,
Alicia Merlino,
Ana Ferreira,
Rossanna Di Maio,
Ana Castro,
Mercedes González,
Hugo Cerecetto
[show abstract]
[hide abstract]
ABSTRACT: In vitro growth inhibitory activity of 21 new 5-ethenylbenzofuroxan derivatives against the protozoan parasite Trypanosoma cruzi, the causative agent of American trypanosomiasis, was studied. The designed compounds possess the previously described exigencies for optimal anti-parasite activity, the 5-ethenylbenzofuroxanyl moiety with different substituents. The synthetic key for preparing the derivatives was the Wittig procedure, that when 5-formylbenzofuroxan was used as the electrophile the corresponding deoxygenated products were marginally generated. Four of the new derivatives displayed remarkable in vitro activities against the epimastigote form of three strains of T. cruzi, Tulahuen 2, CL Brener, and Y. While the three deoxygenated analogues biologically assayed resulted inactives. Unspecific cytotoxicity was evaluated using human macrophages and active derivatives were not toxic at a concentration at least 13 times that of its IC(50) against T. cruzi (CL Brener strain). From the preliminary structure-activity relationship studies lipophilicity and electronic requirements were found relevant to anti-T. cruzi activity. Active compounds are more lipophilic than inactive ones and it was also identified that an optimum value of R Swain-Lupton's descriptor is required for optimal activity.
Bioorganic & Medicinal Chemistry 05/2007; 15(7):2768-81. · 2.92 Impact Factor
-
Lucía Otero, Gabriela Aguirre,
Lucía Boiani,
Ana Denicola,
Carolina Rigol,
Claudio Olea-Azar,
Juan Diego Maya,
Antonio Morello,
Mercedes González,
Dinorah Gambino,
Hugo Cerecetto
[show abstract]
[hide abstract]
ABSTRACT: Rhenium and ruthenium complexes of the type [Re(V)OCl(2)(PPh(3))L] and [Ru(II)Cl(2)(DMSO)(2)L], where L are 5-nitrofurylsemicarbazone derivatives, were prepared in an effort to obtain new anti-trypanosomal agents combining the recognized biological activity of these metals and the trypanocidal activity of the free ligands. Rhenium complexes resulted unstable in aqueous solution not allowing their use as potential drugs. On the other hand, complexation to ruthenium of the bioactive ligands lead to the lack of antiprotozoa activity even though free radical production and redox cycling induction were detected when the compounds were incubated in presence of Trypanosoma cruzi cells. The lack of anti-trypanosomal activity of ruthenium complexes could be explained on the basis of their high protein binding capacity and their high hydrophilicity.
European Journal of Medicinal Chemistry 12/2006; 41(11):1231-9. · 3.35 Impact Factor
-
Carolina Urquiola,
Marisol Vieites, Gabriela Aguirre,
Adoración Marín,
Beatriz Solano,
Gabriel Arrambide,
Pabla Noblía,
María Laura Lavaggi,
María H Torre,
Mercedes González,
Antonio Monge,
Dinorah Gambino,
Hugo Cerecetto
[show abstract]
[hide abstract]
ABSTRACT: New vanadium complexes of the type [V(IV)O(L)(2)], where L are 3-aminoquinoxaline-2-carbonitrile N(1),N(4)-dioxide derivatives, were prepared as an effort to obtain new anti-trypanosomal agents improving the bioactivity of the free ligands. Complexation to vanadium of the quinoxaline ligands leads to excellent antiprotozoal activity, similar to that of the reference drugs nifurtimox and benznidazole and in all cases higher than that of the corresponding free ligands. In addition, it is for the first time that the V((IV))O-quinoxaline complexes are reported as a family of anti-Trypanosoma cruzi agents. Finally, the anti-trypanosomal activity of these vanadium complexes could be explained on the basis of their lipophilicity and the electronic characteristics of the quinoxaline substituents.
Bioorganic & Medicinal Chemistry 09/2006; 14(16):5503-9. · 2.92 Impact Factor
-
Alejandra Gerpe, Gabriela Aguirre,
Lucía Boiani,
Hugo Cerecetto,
Mercedes González,
Claudio Olea-Azar,
Carolina Rigol,
Juan D Maya,
Antonio Morello,
Oscar E Piro,
Vicente J Arán,
Amaia Azqueta,
Adela López de Ceráin,
Antonio Monge,
María Antonieta Rojas,
Gloria Yaluff
[show abstract]
[hide abstract]
ABSTRACT: A series of indazole N-oxide derivatives have been synthesized and their antichagasic and leishmanocidal properties studied. 3-Cyano-2-(4-iodophenyl)-2H-indazole N1-oxide exhibited interesting antichagasic activity on the two parasitic strains and the two parasitic stages evaluated. Furthermore, besides its trypanocidal activity, 3-cyano-2-(4-nitrophenyl)-2H-indazole N1-oxide showed leishmanocidal activity in the three parasitic strains evaluated. To gain insight into the mechanism of action, electrochemical behaviour, ESR experiment, inhibition of parasitic respiration and QSAR were performed.
Bioorganic & Medicinal Chemistry 06/2006; 14(10):3467-80. · 2.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Growth inhibitory activity in vitro of sixteen new 5-nitrofuryl derivatives against the protozoan parasite Trypanosoma cruzi, the causative agent of American trypanosomiasis, was studied. The designed compounds combine in the same molecule the recognized 5-nitrofuryl group, an oxidative stress promoter, and lateral chains that could interact with biomolecules such as trypanothione reductase. Some of the derivatives were found to be very active against the epimastigote form of the parasite, being near to 3.0-fold more active than the reference compound, nifurtimox. Moreover, three-dimensional requirements for activity were clearly observed using a 3D-QSAR study based on a comparative molecular field analysis (CoMFA). The best CoMFA model, r(2) = 0.970 and q(2) = 0.725, points to the importance of a specific hydrogen-bonding pattern around the carbonyl or thiocarbonyl moieties, as well as the requirement for hydrophobic lateral chains. Theoretical pharmacokinetics (Lipinski's rule, PSA) supports further in vivo studies.
European Journal of Medicinal Chemistry 05/2006; 41(4):457-66. · 3.35 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The results of a study on the use of Hansch's series design, cluster methodology, for the generation of new benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as antitrypanosomal compounds are described. In vitro activity of these compounds was tested against Tulahuen 2 strain of Trypanosoma cruzi. Clearly, the Hansch methodology allowed identifying two cluster-substituents suitable for further structural modifications. The most effective drugs, derivatives 11, 18, and 21, with 50% inhibitory concentration (IC(50)) of the same order as that of the reference drug, represent an excellent structural point of chemical modifications for the design of future drugs. Preliminary results from the study of the mechanism of action of these benzofuroxans point to perturbation of the mitochondrial electron chain, inhibiting parasite respiration.
Bioorganic & Medicinal Chemistry 01/2006; 13(23):6324-35. · 2.92 Impact Factor
-
Gabriela Aguirre,
Lucía Boiani,
Mariana Boiani,
Hugo Cerecetto,
Rossanna Di Maio,
Mercedes González,
Williams Porcal,
Ana Denicola,
Oscar E Piro,
Eduardo E Castellano,
Carlos Mauricio R Sant'Anna,
Eliezer J Barreiro
[show abstract]
[hide abstract]
ABSTRACT: Benzofuroxan derivatives have been shown to inhibit the growth of Trypanosoma cruzi, the etiological agent of Chagas' disease. Therefore, 2D- and 3D-QSAR models of their in vitro antichagasic activity were developed. Six new derivatives were synthesized to complete a final set of 26 structurally diverse benzofuroxans. The 2D-QSAR model (r = 0.939, r(adj)(2) = 0.849) was generated using multiple regression analysis of tabulated substituents' physicochemical properties and indicator variables. In addition, a 3D-QSAR model (r(2) = 0.997, q(2) = 0.802) was obtained using a comparative molecular field analysis (CoMFA). Due to the well-known benzofuroxan tautomerism, in both approaches (2D- and 3D-QSAR) it was necessary to include an indicator variable to consider the N-oxide position (I(6)). This parameter was established using low-temperature NMR experiments. Both QSAR models identified the electrophilic character of the substituent alpha-atom as a requirement for activity. Further support was found using a density functional theory (DFT) approach.
Bioorganic & Medicinal Chemistry 01/2006; 13(23):6336-46. · 2.92 Impact Factor
-
Gabriela Aguirre,
Lucía Boiani,
Hugo Cerecetto,
Marcelo Fernández,
Mercedes González,
Ana Denicola,
Lucia Otero,
Dinorah Gambino,
Carolina Rigol,
Claudio Olea-Azar,
Mario Faundez
[show abstract]
[hide abstract]
ABSTRACT: The in vitro growth inhibition activity of new thiosemicarbazone derivatives against the protozoan parasite Trypanosoma cruzi, the causative agent of American trypanosomiasis, are described. The designed compounds combine in the same molecule the thiosemicarbazone function, recently described as a potent cruzain-inhibitor moiety, and the recognised 5-nitrofuryl group, an oxidative stress promoter. Some of the derivatives were found to be very active against the cultured (epimastigote) form of the parasite, being 1.5-1.7-fold more active than the reference compound, Nifurtimox. Free radicals production was detected when the compounds were incubated in presence of mammalian-liver microsomes. The thiosemicarbazones' capacity to act as pharmacophore in the cruzain inhibition process was theoretically analysed. Frontier molecular orbital HOMO was found as an adequate descriptor in this process. Acute in vivo toxicity of two of the more active derivatives was evaluated. The results showed that these compounds are among the most potent 5-nitrofuryl derivatives tested against this parasite thus support further in vivo studies of some of these thiosemicarbazones.
Bioorganic & Medicinal Chemistry 10/2004; 12(18):4885-93. · 2.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Quinoxaline derivatives presented good inhibitor activity of growth of Trypanosoma cruzi in in vitro assays. The 50% inhibitory doses were of the same order of that of Nifurtimox. Derivative 13, a quinoxaline N,N'-dioxide derivative, and the reduced derivatives 19 and 20 were the most cytotoxic compounds against the protozoan. Structural requirements for optimal activity were studied by computational methods. From statistical analysis we could establish a multiple correlation between activity and lipophilic properties and LUMO energy.
Bioorganic & Medicinal Chemistry Letters 08/2004; 14(14):3835-9. · 2.55 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Design, using force-field calculations on the catalytic site of trypanothione reductase from Trypanosoma cruzi, has led to the development of new 5-nitrofuryl derivatives as potential anti-trypanosomal agents. The synthesized compounds were tested in vitro against T. cruzi and more than 75% of the prepared derivatives showed higher activity than nifurtimox. Compounds 5 and 11, hexyl 4-(5-nitrofurfurylidene)carbazate and N-hexyl 3-(5-nitrofuryl)propenamide, showed the highest in vitro trypanocidal effect reported to date for members of the nitrofuran family. Partition coefficients and energies for the single-electron reduction of compounds were theoretically determined. These properties could be not the major cause of the activities' differences. The physicochemical environment around E19, W22, C53 and Y111 residues within the trypanothione binding site of trypanothione reductase resulted a valuable target for the rational design of anti-trypanosomal drugs.
European Journal of Medicinal Chemistry 06/2004; 39(5):421-31. · 3.35 Impact Factor
-
Gabriela Aguirre,
Mariana Boiani,
Hugo Cerecetto,
Alejandra Gerpe,
Mercedes González,
Yolanda Fernández Sainz,
Ana Denicola,
Carmen Ochoa De Ocáriz,
Juan José Nogal,
David Montero,
José Antonio Escario
[show abstract]
[hide abstract]
ABSTRACT: The syntheses and biological evaluation of the first anti-protozoa imidazole N-oxide and benzimidazole N-oxide and their derivatives are reported. They were tested in vitro against two different protozoa, Trypanosoma cruzi and Trichomonas vaginalis. Derivative 7c, ethyl-1-(i-butyloxycarbonyloxy)-6-nitrobenzimid-azole-2-carboxylate, displayed activity on both protozoa. Lipophilicity and redox potential were experimentally determined in order to study the relationship with activity of the compounds. These properties are well related with the observed bioactivity. Imidazole and benzimidazole N-oxide derivatives are becoming leaders for further chemical modifications and advanced biological studies.
Archiv der Pharmazie 06/2004; 337(5):259-70. · 1.71 Impact Factor
